Ketamine administration in depressive disorders: a systematic review and meta-analysis.
about
Pharmacological interventions for self-harm in adultsInterventions for self-harm in children and adolescentsKynurenine pathway metabolites and suicidalityPharmacological Approaches for Treatment-resistant Bipolar DisorderRemission From Behavioral Dysregulation in a Child With PTSD After Receiving Procedural KetamineThe role of inflammation in suicidal behaviourThe International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise AlgorithmR-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effectsDifferential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network.The neuroscience of depression: implications for assessment and intervention.Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case SeriesA pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trialUse of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain.Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial.Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations.Suicide and suicidal behaviourBeyond serotonin: newer antidepressants in the future.Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study).Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart reviewCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsSingle-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial).Increased PKC activity and altered GSK3β/NMDAR function drive behavior cycling in HINT1-deficient mice: bipolarity or opposing forces.Multistage drug effects of ketamine in the treatment of major depression.The promise of ketamine for treatment-resistant depression: current evidence and future directions.Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled TrialsEvidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review.Ketamine modulates subgenual cingulate connectivity with the memory-related neural circuit-a mechanism of relevance to resistant depression?Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.Ketamine for treatment-resistant depression: recent developments and clinical applications.KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.Suicidality and Activation of the Kynurenine Pathway of Tryptophan Metabolism.Is there a future for other glutamate receptor modulators in the pharmacotherapy of mood disorders?Can neurophysiologic measures serve as biomarkers for the efficacy of repetitive transcranial magnetic stimulation treatment of major depressive disorder?
P2860
Q24186543-0BD3542E-FE9A-4F06-93A6-BC0BD2E9A707Q24187033-E74B5791-A72A-470F-AC52-18D1BD4BFC3BQ26773067-6B208D95-3E1B-415C-9662-95CE04C765A5Q26783002-07E99527-C88B-451E-8178-6C325D268F2EQ26799619-EC1A83E6-A276-4949-A3C8-ADD82E19E5B7Q26800426-B884B891-9986-499A-B50F-25FB16819938Q28066714-9963232D-BFE6-459C-B1D9-A08AFF08AA09Q28266846-8F6D468F-76A7-44E4-A20F-B60CEB8CC68CQ30357854-BF68090C-DF52-4648-80F6-DC5572D26EA4Q30399725-4C0747D9-B8CD-43ED-9767-761FC06FEFE6Q30491706-AAEF736C-E630-4690-8E9B-54A9B6FB52BFQ30987882-73C316AD-5EF5-490A-B926-BCD9126914ACQ33607667-1B67BACC-DA3C-4AEA-A052-EB7880E51585Q33693374-E9134080-DA4D-4431-BD82-E2FF7CB4C29EQ33721019-49B2ECDF-49A6-4903-94F9-81EEE957C78AQ33747674-2DA20C81-5CF2-4171-9DD7-E14B4EB27451Q34466310-DEFAD68E-6D88-4F25-8A49-1155001C0348Q34494779-EB6B98EE-9C23-457A-A8E5-456DF5FE5A66Q34557706-FE5B2603-0364-421E-8663-377EE7A54C16Q35547495-3DDFBC8A-A3D7-45EB-8669-DDD41462D1F2Q35816486-32CD2462-A6C1-458B-9F97-BD5038355C90Q36176755-7CACD0CD-6ADC-4DA7-AE39-D74A6AED230FQ37197216-A6BD251D-DBA7-4B6F-8779-5359B6BA3ACDQ37424333-8AC54062-022D-447E-84EC-24DBC89613A7Q37498103-2762EC10-1337-44F5-8C6F-DD479E95F24DQ37668134-C3DBCA84-3D87-41BE-9D6F-37C19C202726Q38248776-A66134D8-E123-4365-8165-F805C962DDEEQ38343315-63E96632-FC12-48A9-930E-758820FFC600Q38377259-B4657EA0-F53A-484A-A2A9-2FB0CFA3EB1DQ38476909-845C2AC1-1177-4F42-B978-F89CF6D1C537Q38633125-ABA03467-C4D7-4136-B56C-1B8B280DDCC1Q38647409-F086ECF0-C7C6-450F-B3ED-76BB4D0C06ACQ38787388-2EB52A04-4EA6-48E1-810A-78EC7BF276B6Q38800172-E6F819E3-3B4F-45C5-B91A-7A07DC4667C1Q38803371-2E00942B-CD22-4DF3-9629-A37EFBB57A7CQ38803429-28C868FD-82E0-4E7E-9EA5-4BFA66F5B43CQ38838637-FE750716-ED20-4D5D-B193-64D7B8CE6131Q38843530-B2D53956-58A0-4E46-B54C-AB848A519B22Q38860021-B05BA2A3-A4C9-4D5B-B909-BC6026F57395Q38864824-41440A5C-903B-4BB2-A8FC-E8360D8F4184
P2860
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
@en
type
label
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
@en
prefLabel
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
@en
P2093
P2860
P50
P1433
P1476
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
@en
P2093
Alexandra Macgregor
Anderson Loundou
Corentin Rabu
Laurent Boyer
Marie Brittner
Matthieu Roger
Mocrane Abbar
Philippe Courtet
P2860
P2888
P304
P356
10.1007/S00213-014-3664-5
P577
2014-07-20T00:00:00Z
P5875
P6179
1008340109